Polyhydroxyalkanoates: Materials for delivery systems

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 5, Issue 3, 1998, Pages 167-177

  Nobes, G A R ^a   Marchessault, R H ^a   Maysinger, D ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Anticancer; Antiviral; Biodegradable; Biopolyesters; Microsphere

Indexed keywords

2',3' DIACYL 5 FLUORO 2' DEOXYURIDINE; ALCARUBICIN; ANTINEOPLASTIC AGENT; ETOPOSIDE; FLUORESCEIN DERIVATIVE; LOMUSTINE; POLY(3 HYDROXYBUTYRIC ACID); POLY(DESAMINOTYROSYL TYROSINE HEXYL ESTER); POLY(ORTHO ESTER); POLY(SEBACIC ACID HEXADECANEDIOIC ACID ANHYDRIDE); POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; PROGESTERONE; STAPHYLOCOCCUS VACCINE; SULFAMETHIZOLE; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BIODEGRADATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; PRIORITY JOURNAL; REVIEW;

EID: 0031706291     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.3109/10717549809052032     Document Type: Review

References (54)

1. Dawes, E. A. 1988. Polyhydroxybutyrate, an intriguing biopolymer. Biosci. Rep. 8, 537-547.
2. Lee, S. Y. 1996. Plastic bacteria? Progress and prospects for polyhydroxyalkanoate production in bacteria. TIBTECH 14, 431-438.
3. Müller, H.-M., and Seebach, D. 1993. Poly(hydroxyalkanoates): a fifth class of physiologically important organic biopolymers? Angew. Chim. Intl. Ed. Engl. 32, 477-502.
4. Steinbüchel, A., and Valentin, H. 1995. Diversity of bacterial polyhydroxyalkanoic acids. FEMS Microbiol. Lett. 128, 219-228.
5. Poirier, Y., Nawrath, C., and Somerville, C. 1995. Production of polyhydroxyalkanoates, a family of biodegradable plastics and elastomers, in bacteria and plants. Bio/Technology 13, 142-150.
6. Reusch, R. N. 1989. Poly-β-hydroxybutyrate/calcium polyposphate complexes in eukaryotic membranes. Proc. Soc. Exp. Biol. Med. 191, 377-381.
7. Reusch, R. N. 1995. Low molecular weight complexed poly(3-hydroxybutyrate): a dynamic and versatile molecule in vivo. Can. J. Microbiol. 41 (Suppl. 1):50-54.
8. Huang, R., and Reusch, R. N. 1996. Poly(3-hydroxybutyrate) is associated with specific proteins in the cytoplasm and membranes of Escherichia coli. J. Biol. Chem. 271, 22196-22202.
9. Jackson, D. E., and Srienc, F. 1994. Novel methods to synthesize polyhydroxyalkanoates. Ann. N. Y. Acad. Sci. 745 (Biochem. Eng. VII):134-148.
10. Rosato, D. V. 1983. In Biocompatible Polymers, Metals, and Composites, edited by M. Szycher. Technomic Publ. Lancaster, PA.
11. Williams, D. F. 1987. Definitions in biomaterials: Proceedings of a consensus conference of the European society for Biomaterials. New York: Elsevier.
12. Engelberg, I., and Kohn, J. 1991. Physico-mechanical properties of degradable polymers used in medical applications: a comparative study. Biomaterials 12, 290-304.
13. Grijpma, D. W., Zondervan, G. J., and Pennings, A. J. 1991. High molecular weight copolymers of L-lactide and ∈-caprolactone as biodegradable elastomeric implant materials. Polym. Bull. 25, 327-333.
14. Grijpma, D. W., and Pennings, A. J. 1991. Polymerization temperature effects on the properties of L-lactide and ∈-caprolactone copolymers. Polym. Bull. 25, 335-341.
15. Ratner, B. D., Hoffman, A. S., Schoen, F. J., and Lemons, J. E. 1996. Biomaterials science: An introduction to materials in medicine. New York: Academic.
16. Mathiowitz, E., Jacob, J. S., Jong, Y. S., Carino, G. P., Chickering, D. E., Chaturvedi, P., Santos, C. A., Vijayaraghavan, K., Montgomery, S., Bassett, and Morrell, C. 1997. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386, 410-414.
17. Domb, A. J., Mathiowitz, E., Ron, E., Giannos, S., and Langer, R. 1991. Polyanhydrides, IV: unsaturated and crosslinked polyanhydrides. J. Polym. Sci., Part A, Polym. Chem. 29, 571-579.
18. Campbell, P., Glover, G. L., and Gunn, J. M. 1980. Inhibition of intracellular protein degradation by pepstatin, poly(L-lysine) and pepstatinyl-poly(L-lysine). Arch. Biochem. Biophys. 203, 676-680.
19. Van Heeswijk, W. A. R., Hoes, C. J. T., Stoffer, T., Eenink, M. J. D., Potman, W., and Feijen, J. 1985. The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin, Part 1. J. Controlled Release 1, 301-315.
20. Holland, S. J., Tighe, B. J., and Gould, P. L. 1986. Polymers for biodegradable medical devices, 1: the potential of polyesters as controlled macromolecular release systems. J. Controlled Release 4, 155-180.
21. Marchessault, R. H., Morikawa, H., Revol, J. F., and Bluhm, T. L. 1984. Physical properties of a naturally occuring biopolyester: poly(β-hydroxybutyrate)/poly(β-hydroxyvalerate). Macromolecules 17, 1882-1887.
22. Lehninger, A. L. 1975. Pp. 831-845 in Biochemistry, 2d ed. New York: Worth.
23. Zubay, G. 1988. Pp. 610-611 in Biochemistry. 2d ed. New York: Macmillan.
24. Pawan, G. L. S., and Semple, S. J. G. 1983. Effect of 3-hydroxybutyrate in obese subjects on very-low-energy diets and during therapeutic starvation. Lancet 15-17.
25. Koosha, F., Muller, R. H., and Davis, S. S. 1989. Polyhydroxybutyrate as a drug carrier. Crit. Rev. Therapeut. Drug Carrier Systems 6, 117-130.
26. Doyle, C., Tanner, E. T., and Bonfield, W. 1991. In vitro and in vivo evaluation of PHB and of PHB replaced with hydroxypapitate. Biomaterials 12, 841-847.
27. Embleton, J. K., and Tighe, B. J. 1992a. Polymers for biodegradable medical devices, IX: microencapsulation studies; effects of polymer composition and process parameters on poly-hydroxybutyrate-hydroxyvalerate microcapsule morphology. J. Microencapsul. 9, 73-87.
28. Embleton, J. K., and Tighe, B. J. 1993. Polymers for biodegradable medical devices, X: microencapsulation studies: control of poly-hydroxybutyrate-hydroxyvalerate microcapsules porosity via polycaprolactone blending. J. Microencapsul. 10, 341-352.
29. Embleton, J. K., and Tighe, B. J. 1992b. Regulation of polyester microcapsule morphology. Pp. 45-54 in Drug Targeting and delivery (microencapsulation of drugs) edited by T. Whately. Philadelphia, PA: Harwood Academic.
30. Knowles, J. C., and Hastings, G. W. 1991. In vitro degradation of a PHB/PHV copolymer and a new technique for monitoring early surface changes. Biomaterials 12, 210-214.
31. Miller, N. D., and Williams, D. F. 1987. On the biodegradation of poly-β-hydroxybutyrate (PHB) homopolymer and poly-β-hydroxybutyrate-hydroxyvalerate copolymers. Biomaterials 8, 129-137.
32. Yasin, M., Holland, S. J., Jolly, A. M., and Tighe, B. J. 1989. Polymers for biodegradable medical devices, VI: hydroxybutyrate-hydroxyvalerate copolymers: accelerated degradation of blends with polysaccharides. Biomaterials 10, 400-412.
33. Atkins, T. W., and Peacock, S. J. 1997. In vitro biodegradation of polyhydroxybutyrate-hydrooxyvalerate microcapsules exposed to Hank's buffer, newborn calf serum, pancreatin and synthetic gastric juice. J. Micoencapsul. 14, 35-49.
34. Behrend, D., Michalik, I., Kramp, B., Haubold, A., and Schmitz, K. P. 1997. Changes in physicochemical properties of poly-β-hydroxybutyrate after long-term implantation in the rat. 23rd Meeting of the Society for Biomaterials, 30 April-4 May, New Orleans, LA.
35. Bissery, M.-C., Valeriote, F., and Thies, C. 1984. In vitro and in vivo evaluation of CCNU-loaded microspheres prepared from poly((±)-lactide) and poly(β-hydroxybutyrate). Pp. 217-227 in Microspheres and drug therapy: Pharmaceutical, immunological and medical aspects, edited by S. S. Davis, L. Illum, J. G. McVie, and E. Tomlinson. New York: Elsevier Science.
36. Juni, K., Nakano, M., and Kubota, M. 1986. Controlled release of aclarubicin, an anticancer antibiotic, from poly-β-hydroxybutyric acid microspheres. J. Controlled Release 4, 25-32.
37. Kawaguchi, T., Tsugane, A., Higashide, K., Endoh, H., Hasegawa, T., Kanno, H., Seki, T., Juni, K., Fukushima, S., and Nakano, M. 1992. Control of drug release with a combination of prodrug and polymer matrix: antitumor activity and release profiles of 2′,3′-diacyl-5-fluoro-2′-deoxyuridine from poly(3-hydroxybutyrate) microspheres. J. Pharmaceut. Sci. 81, 508-512.
38. Gangrade, N., and Price, J. C. 1991. Poly(hydroxybutyrate-hydroxyvalerate) microspheres containing progesterone: preparation, morphology and release properties. J. Microencapsul. 8, 185-202.
39. Brophy, M. R., and Deasy, P. B. 1986. In vitro and in vivo studies on biodegradable polyester microparticles containing sulfamethizole. Int. J. Pharmaceut. 29, 223-231.
40. Gürsel, I., and Hasirci, V. 1995. Properties and drug release behavior of poly(3-hydroxybutyric acid) and various poly(3-hydroxybutyrate-hydroxyvalerate) copolymer microcapsules. J. Microencapsul. 12, 185-193.
41. Saad, B., Ciardelli, G., Matter, S., Welti, M., Uhlschmid, G. K., Neuenschwander, P., and Suter, U. W. 1996. Characterization of the cell response of cultured macrophages and fibroblasts to particles of short-chain poly[(R)-3-hydroxybutyric acid]. J. Biomed. Materials Res. 30, 429-439.
42. Rivard, C. H., Chaput, C., Rhalmi, S., and Selmani, A. 1996. Bio-absorbable synthetic polyesters and tissue regeneration: a study of three-dimensional proliferation of ovine chondrocytes and osteoblasts. Ann. Chir. 50, 651-658.
43. Deasy, P. B. 1984. Microencapsulation and related drug processes. New York: Dekker.
44. Allen, T. A. 1994. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends in Pharm. Sci. 15, 215-220.
45. Kubota, M., Nakano, M., and Juni, K. 1988. Mechanism of enhancement of the release rate of alcarubicin from poly-β-hydroxybutyric acid microspheres by fatty acid esters. Chem. Pharmaceut. Bull. 36, 333-337.
46. Abe, H., Doi, Y., and Yamamoto, Y. 1992. Controlled release of lastet, an anticancer drug, from poly(3-hydroxybutyrate) microspheres containing acylglycerols. Macromol. Rep. A29 (Suppl. 3):229-235.
47. Derman, R. 1989. Oral contraceptives: a reassessment. Obstet. Gynecol. Surv. 44, 662-668.
48. Drife, J. O. 1989. New developments on contraception. Progr. Obstet. Gynaecol. 7, 249-261.
49. Chetkowski, R., and Meldrum, D. R. 1986. Biologic effects of transdermal estradiol. N. Engl. J. Med. 314, 1615-1620.
50. Hallagan, J. B., Hallagan, L. F., and Snyder, M. 1989. Anabolic-androgenic steroid use by athletes. N. Engl. J. Med. 321, 1042-1046.
51. Williams, J. K. and Adams, M. R. 1997. Estrogens, progestins and coronary artery reactivity. Nat. Med. 3, 273-274.
52. Eldridge, J. H., Hammond, C. J., Meulbrook, J. A., Staas, J. K., Gilley, R. M., and Tice, T. R. 1990. Controlled vaccine release in the gut-associated lymphoid tissues, I: Orally administered biodegradable microspheres target the Payer's patches. J. Controlled Release 11, 205-214.
53. Gerngross, T. U., and Martin, D. P. 1995. Enzyme-catalyzed synthesis of poly[(R)-(-)-3-hydroxybutyrate]: formation of macroscopic granules in vitro. Proc. Natl. Acad. Sci. USA 92, 6279-6283.
54. Omri, A., Ravaoarinoro, M., and Poisson, M. 1995. Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 36, 631-639.